20126 ⎘
Medicinal preparations characterised by special physical form; Pills, tablets, discs, rods; Dragees; Coated pills or tablets, e.g. with film or compression coating; Coating materials; Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone Poly(meth)acrylates
MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE
#2Controlled Release Pharmaceutical Composition
#3CAFFEINE SUSTAINED RELEASE FORMULATION
#4METHYLPHENIDATE MODIFIED RELEASE FORMULATIONS
#5LARAZOTIDE FORMULATIONS
#6ENTERIC COATED PITOLISANT FORMULATIONS AND METHODS OF USE
#7COMPOSITIONS TO MODULATE THE GUT MICROBIOTA AND TO MANAGE WEIGHT
#8IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS
#9COMBINATION FORMULATION OF CEDAZURIDINE
#10PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER
#11Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-Enenitrile
#12PHARMACEUTICAL COMPOSITIONS
#13PHARMACEUTICAL COMPOSITIONS
#14Compositions and methods for treating bile acid malabsorption
#15USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN
#16MODIFIED RELEASE NICORANDIL COMPOUND FORMULATIONS
#17PHARMACEUTICAL COMPOSITIONS
#18PHARMACEUTICAL COMPOSITIONS
#19DOSAGE FORM WITH DRUG RELEASE AT PH 3 TO 6 USING DOUBLE COATING SYSTEM WITH AT LEAST ONE RELEASE ACCELERATION AGENT
#20Methods and Compositions for Oral Administration of Proteins
#21PROCESS TO ENHANCE THE BIOACTIVITY OF ASHWAGANDHA EXTRACTS
#22ORAL COMPOSITION COMPRISING NICOTINAMIDE
#23PHARMACEUTICAL COMPOSITIONS
#24Compositions and methods for treating bile acid malabsorption
#25SUSTAINED RELEASE COMPOSITIONS OF ENDOXIFEN
#26PHARMACEUTICAL COMPOSITIONS
#27COATED TABLETS FOR PH-DEPENDENT RELEASE OF BENZGALANTAMINE
#28Improved Thiopurine Formulation and Treatment Methods
#29SOLID ORAL COMPOSITION CONTAINING DYES FOR USE IN ENDOSCOPIC DIAGNOSIS
#30ENTERIC COATED PITOLISANT FORMULATIONS AND METHODS OF USE
#31METHOD FOR TREATING METABOLIC DISORDERS BY ILEUM-TARGETED DELIVERY OF ENDOTOXIN SEQUESTRANT
#32ENTERIC COATED TABLET
#33NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE
#34TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS
#35ORAL DOSAGE FORMS OF A THERAPEUTICALLY ACTIVE ACID-LABILE SALT AND METHODS AND USES RELATED THERETO
#36FORMULATIONS FOR SMALL INTESTINAL DELIVERY OF RSV AND NOROVIRUS ANTIGENS
#37ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
#38Delayed Release Compositions of Linaclotide
#39DRUG DELIVERY SYSTEM FOR THE TREATMENT OF FEMALE SEXUAL INTEREST AND AROUSAL DISORDER
#40METHOD FOR TREATING CANCER
#41COMPOSITIONS FOR DELIVERY OF REBOXETINE
#42Pharmaceutical compositions
#43ROOM TEMPERATURE STABLE ORAL CALCITONIN FORMULATION
#44Monomethylfumarate Prodrug Compositions
#455-AMINOLEVULINIC ACID FOR THE LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASE
#46FORMULATIONS FOR SMALL INTESTINAL DELIVERY
#47TEBIPENEM PIVOXIL IMMEDIATE AND MODIFIED RELEASE ORAL DOSAGE FORMS
#48GASTRO-RETENTIVE ORAL DOSAGE UNIT CONTAINING A LOCAL ANAESTHETIC
#49GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMS
#50ALKALINE PHOSPHATASE FORMULATIONS
#51COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
#52Tamper Resistant Immediate Release Formulations
#53ORAL RIFAMYCIN SV COMPOSITIONS
#54PHARMACEUTICAL PREPARATION EXCELLENT IN LIGHT STABILITY AND DISSOLUTION PROPERTY
#55Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
#56PHARMACEUTICAL COMPOSITIONS OF OZANIMOD
#57CALCIUM LACTATE COMPOSITIONS AND METHODS OF USE
#58MAGNESIUM PICOLINATE COMPOSITIONS AND METHODS OF USE
#59SOLID ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING COMPLEX MONOLITHIC MATRICES FOR CHRONOTROPIC ADMINISTRATION OF MEDICAMENTS IN THE GASTROINTESTINAL TRACT
#60MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS
#61Polymorphs of phenyl pyrrole aminoguandium salts
#62Methods and Compositions Relating to Microbial Treatment and Diagnosis of Disorders
#63PROTECTIVE COATING FOR MOISTURE SENSITIVE PHARMACEUTICAL COMPOSITIONS
#64COMPACTABLE ORAL FORMULATIONS OF IBUTAMOREN
#65TREATMENT OF GASTROINTESTINAL DISORDERS
#66TASTE MASKED COMPOSTIONS OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND ORALLY DISENTEGRATING TABLET COMPRISING THE SAME
#67Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile
#68USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN
#69MODIFIED RELEASE NICORANDIL COMPOUND FORMULATIONS
#70ENTERIC TABLET CONTAINING DIMETHYL FUMARATE
#71Pharmaceutical compositions
#72METHOD AND COMPOSITION FOR LOWERING TOTAL SYSTEMIC CHOLESTROL, LDL CHOLESTEROL, AND NON-HDL CHOLESTEROL
#73COATED SOLID PHARMACEUTICAL PREPARATION
#74COMPACTABLE ORAL FORMULATIONS OF IBUTAMOREN
#75TREATMENT OF GASTROINTESTINAL DISORDERS
#76MODIFIED RELEASE FORMULATIONS OF METHADONE AND ITS ISOMERS, ESMETHADONE AND LEVOMETHADONE AND DERIVATIVES
#77Pharmaceutical compositions
#78PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF
#79GASTROINTESTINAL HEALTH COMPOSITION
#80Low-Dose Stable Formulations of Linaclotide
#81IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS
#82PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE AS ACTIVE INGREDIENT
#83Delayed Release Compositions of Linaclotide
#84ORAL DELAYED BURST FORMULATION OF LOW-DOSE NALTREXONE AND METHODS FOR TREATING FIBROMYALGIA AND LONG COVID
#85ENTERIC COATED TABLET
#86SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES
#87PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER
#88HIGH-STRENGTH ORAL TAXANE COMPOSITIONS AND METHODS
#89Pharmaceutical compositions
#90Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them
#91Compositions and methods for treating metabolic disorders
#92INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
#93Oral formulations of cytidine analogs and methods of use thereof
#94ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
#95Process to enhance the bioactivity of Ashwagandha extracts
#96Methylphenidate Extended Release Chewable Tablet
#97NOVEL METHACRYLATE COPOLYMER AND COMPOSITIONS COMPRISING IT
#98ADEMETIONINE AND CANNABIDIOL BASED SOLID PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARING IT
#99ENTERIC-COATED PREPARATION COMPRISING PIRFENIDONE HAVING IMPROVED SAFETY AND STABILITY, AND METHOD FOR PREPARING SAME
#100Delayed Release Compositions of Linaclotide
#101Oral rifamycin SV compositions
#102SOLID ORAL COMPOSITION CONTAINING DYES FOR USE IN ENDOSCOPIC DIAGNOSIS
#103METHOD OF TREATMENT USING META-ARSENITE
#104Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
#105PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS
#106Process for mesalazine solid formulations
#107Enriched Withania somnifera Based Dietary Composition and a Method Thereof
#108Tesofensine and beta blocker combination formulations
#109BIOAVAILABLE POLYAMINES
#110DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASE
#111EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE
#112ANTI-METHANOGENIC COMPOSITIONS AND USES THEREOF
#113COMPOSITIONS AND METHODS FOR REDUCING CYTOKINE EXPRESSION
#114Dosage form for use in treating or preventing of a disease
#115DOSAGE FORM COMPRISING AN ALKALINE AGENT AND AN ENTERIC COATING LAYER
#116Room temperature stable oral calcitonin formulation
#117VETERINARY FORMULATIONS COMPRISING RAPAMYCIN AND METHODS OF USING THE SAME FOR TREATING ANIMAL DISEASE
#118Gastro-resistant controlled release oral dosage forms
#119COMPOSITION AND METHOD FOR TREATMENT OF DIABETES
#120Formulations for small intestinal delivery of RSV and norovirus antigens
#121LARAZOTIDE FORMULATIONS
#122PHARMACEUTICAL ORAL DOSAGE FORMS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED DISEASES THROUGH ORCHESTRATED RELEASE OF ENTEROKINES
#123Compositions for delivery of reboxetine
#124METHODS OF USING RIFAMYCIN SV FOR THE TREATMENT OF SICKLE CELL DISEASE
#125MONOMETHYLFUMARATE PRODRUG COMPOSITIONS
#126EXTENDED RELEASE COMPOSITION OF TOFACITINIB
#127GASTRORETENTIVE DOSAGE FORMS OF LEVODOPA AND CARBIDOPA
#128COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
#129PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HAVING DOUBLE-RELEASE PROFILE
#130Benzonatate modified release solid tablets and capsules
#1315-AMINOLEVULINIC ACID FOR THE LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASE
#132Modified or Targeted Release Formulations of Linaclotide
#133Articles and methods for administration of therapeutic agents
#134Tacrolimus for improved treatment of transplant patients
#135Sustained release compositions comprising liothyronine
#136Calcium lactate compositions and methods of use
#137Sustained release compositions of endoxifen
#138PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE FOR ADMINISTRATION AT A LOW DAILY DOSE
#139METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
#140ALCOHOL-RESISTANT DRUG FORMULATIONS
#141Sustained release solid dosage forms for modulating the colonic microbiome
#142ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
#143CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#144CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES
#145ENTERIC TABLET CONTAINING DIMETHYL FUMARATE
#146Oral formulations of cytidine analogs and methods of use thereof
#147PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX
#148COMPOUNDS FOR PRENATAL TREATMENT COMPRISIING A NATAL VITAMIN AND ASPIRIN AND METHOD FOR MAKING AND USING THE SAME
#149FORMULATIONS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF
#150SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ADMINISTRATION OF MESALAZINE OR DERIVATIVES THEREOF
#151SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR CHRONOTROPIC ADMINISTRATION OF DIPEPTIDYL PEPTIDASE IV INHIBITORS
#152Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
#153Low-Dose Stable Formulations of Linaclotide
#154Tamper resistant immediate release formulations
#155METHOD OF PRODUCING A DELAYED RELEASE DRUG FORMULATION
#156Pharmaceutical compositions
#157SOLID ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING COMPLEX MONOLITHIC MATRICES FOR CHRONOTROPIC ADMINISTRATION OF MEDICAMENTS IN THE GASTROINTESTINAL TRACT
#158COLONIC DRUG DELIVERY FORMULATION
#159Methods and compositions relating to microbial treatment and diagnosis of disorders
#160DUAL RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMBINATION OF A BETA-3 ADRENORECEPTOR AGONIST AND A MUSCARINIC RECEPTOR ANTAGONIST
#161Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
#162Pharmaceutical Compositions Comprising Dimethyl Fumarate
#163ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS
#164METHOD FOR TREATING PRIMARY SCLEROSING CHOLANGITIS
#165Methods and Compositions for Oral Administration of Exenatide
#166Thrombin inhibitors, formulations, and uses thereof
#167SOLID CANNABINOID FORMULATION FOR ORAL ADMINISTRATION
#168PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE FOR ADMINISTRATION AT A LOW DAILY DOSE
#169EXTENDED RELEASE DOSAGE FORMS OF PREGABALIN
#170Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
#171Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
#172Extended release compositions comprising pyridostigmine
#173Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
#174Alkaline phosphatase formulations
#175CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#176ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE
#177Methylphenidate extended release chewable tablet
#178SOLID SELF-EMULSIFYING CANNABINOID COMPOSITIONS
#179Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
#180Methods and compositions to modulate the gut microbiota and to manage weight
#181Methods and compositions to modulate the gut microbiota and to manage weight
#182PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOF
#183METHODS AND COMPOSITIONS TO MODULATE THE GUT MICROBIOTA AND TO MANAGE WEIGHT
#184FORMULATION HAVING IMPROVED PH-DEPENDENT DRUG-RELEASE CHARACTERISTICS CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#185OXYCODONE AND METHYLNALTREXONE MULTIPARTICULATES AND SUSPENSIONS CONTAINING THEM
#186Process to enhance the bioactivity of Ashwagandha extracts
#187Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
#188Methylphenidate extended release chewable tablet
#189ENTERIC COATED TABLET
#190ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS
#191Pharmaceutical composition for modified release
#192CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG
#193Composition for use in the treatment of intestinal alterations
#194Method for treating cancer
#195Sustained release solid dosage forms for modulating the colonic microbiome
#196Tacrolimus for improved treatment of transplant patients
#197Tacrolimus for improved treatment of transplant patients
#198ARTICLES AND METHODS FOR ADMINISTRATION OF THERAPEUTIC AGENTS
#199Methylphenidate extended release chewable tablet
#200Intestinal alkaline phosphatase formulations
#201Tesofensine and beta blocker combination formulations
#202Pharmaceutical composition comprising meta arsenite and method of manufacture
#203Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
#204Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
#205ENTERIC COATED PHARMACEUTICAL COMPOSITION AND USE THEREOF
#206Extended release compositions comprising pyridostigmine
#207Pharmaceutical preparation excellent in light stability and dissolution property
#208Compositions
#209Bioavailable polyamines
#210PHARMACEUTICAL FORMULATION FOR A SOLID DOSAGE FORM OF OPIOID RECEPTOR ANTAGONISTS
#211CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION
#212Methods and compositions relating to microbial treatment and diagnosis of disorders
#213Enterically coated cysteamine, cystamine and derivatives thereof
#214PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER
#215Alcohol-resistant drug formulations
#216Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
#217Oral delivery of GLP-1 peptide analogs
#218Anti-methanogenic compositions and uses thereof
#219ISOTOPOLOGUES OF 5-AZACYTIDINE
#220Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#221Solid dispersions comprising tacrolimus
#222PHARMACEUTICAL COMPOSITIONS FOR TREATING DIABETES AND PREPARATION METHOD THEREOF
#223Oral rifamycin SV compositions
#224SOLID COMPOSITION FOR THE ORAL ADMINISTRATION OF DYES AND DIAGNOSTIC USE THEREOF
#225Methods and compositions relating to microbial treatment and diagnosis of disorders
#226Methods and compositions relating to microbial treatment and diagnosis of disorders
#227Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#228Pharmaceutical compositions
#229Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
#230PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
#231Delayed release drug formulation
#232PHARMACEUTICAL COMPOSITION PARTICLES, ORALLY DISINTEGRATING PREPARATION CONTAINING SAME, AND METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITION PARTICLES
#233Pharmaceutical compositions comprising dimethyl fumarate
#234Methylphenidate extended release chewable tablet
#235Benzonatate modified release solid tablets and capsules
#236METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT
#237DIHYDROMYRICETIN HOT MELT EXTRUSION FORMULATIONS AND METHODS FOR FORMING THEM
#238Pharmaceutical formulation containing gelling agent
#239SOLID ORAL COMPOSITION CONTAINING DYES FOR USE IN ENDOSCOPIC DIAGNOSIS
#240Tesofensine and beta blocker combination formulations
#241Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
#242Isotopologues of 5-azacytidine
#243Method of treating heart failure with preserved ejection fraction by administering milrinone
#244COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
#245Formulations of cycloserine compounds and applications thereof
#246SOLID ORAL COMPOSITION CONTAINING DYES
#247Composition for use in the treatment of intestinal alterations
#248Pharmaceutical compositions comprising a fumaric acid ester and method for the preparation thereof
#249Low-Dose Stable Formulations of Linaclotide
#250Compositions of gallium (III) complexes for oral administration
#251ORAL DOSAGE FORM WITH DRYING AGENT FOR DELIVERY OF ACTIVE AGENT
#252Tebipenem pivoxil immediate and modified release oral dosage forms
#253Lactuloside compounds and preparation and use thereof
#254IMPROVED COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE
#255COMPOSITIONS FOR DELIVERY OF REBOXETINE
#256Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
#257Antisense Compositions and Methods of Making and Using Same
#258POWDERS AND TABLETS COMPRISING OMEGA-3 FATTY ACID DERIVATIVES AND METHODS FOR THEIR PRODUCTION
#259PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
#260Modified or Targeted Release Formulations of Linaclotide
#261Controlled release pharmaceutical compositions comprising a fumaric acid ester
#262Anti-methanogenic compositions and uses thereof
#263COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE
#264Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
#265Solid pharmaceutical compositions and processes for their production
#266Acidifying coatings and disintegration-resistant substrates coated therewith
#267Methods and Compositions for Rectal Administration of Exenatide
#268Calcium lactate compositions and methods of use
#269COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
#270ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS
#271Extended release dosage forms of pregabalin
#272EXTENDED RELEASE DRUG FORMULATION WITH OVERDOSE PROTECTION AND ABUSE DETERRENCE
#273Compositions and methods for reducing overdose
#274Modified-release dosage forms of 5-HTagonists useful for weight management
#275Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs
#276Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
#277Monomethylfumarate Prodrug Compositions
#278Formulation having improved pH-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
#279Isotopologues of 5-azacytidine
#280MODIFIED RELEASE FORMULATIONS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE
#281Controlled-release solid dosage forms of mesalamine
#282DELAYED-RELEASE FORMULATIONS, METHODS OF MAKING AND USE THEREOF
#283Pharmaceutical suspension dosage form of benzimidazole compounds and process of preparation thereof
#284PHARMACEUTICAL COMPOSITIONS CONFIGURED TO DETER DOSAGE FORM SPLITTING
#285PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE FOR ADMINISTRATION AT A LOW DAILY DOSE
#286CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
#287COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT
#2885-aminosalicylic acid capsule formulation
#289Controlled release and taste masking oral pharmaceutical composition
#290Treatment of Neurodegeneration and Neuroinflammation
#291Room temperature stable oral calcitonin formulation
#292ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS
#293FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
#294PHARMACEUTICAL MATRIX FORMULATIONS COMPRISING DIMETHYL FUMARATE
#295COMPOSITION FOR DELIVERY OF ACTIVE AGENTS TO AN ANIMAL
#296Tamper resistant pharmaceutical formulations
#297PROCESS TO ENHANCE THE BIOACTIVITY OF ASHWAGANDHA EXTRACTS
#298Process for mesalazine solid formulations
#299Compounds for prenatal treatment comprising a natal vitamin and aspirin and methods for making and using the same
#300CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITIONS